Site News

Added 15 hours ago Drug news

NICE extends recommendation for Strensiq (asfotase alfa) to treat people with paediatric-onset hypophosphatasia.- Alexion Pharma

NICE has published draft guidance recommending the drug asfotase alfa (also called Strensiq and made by Alexion Pharma UK) for...

Added 1 day ago Drug news

EU Commission approves Kyntheum (brodalumab) of moderate-to-severe plaque psoriasis.- Leo Pharma

AstraZeneca and MedImmune, announced that its partner Leo Pharma has been granted full marketing authorisation in all 28 EU member...

Added 1 day ago Drug news

Rolling submission to FDA started for CAM 2038 (buprenorphine depots) in Opioid Use Disorder- Braeburn Pharmaceuticals and Camurus

Braeburn Pharmaceuticals and Camurus announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S....

Added 1 day ago Drug news

Study suggests Reminyl XL/Razadyne (galantamine hydrobromide) provides benefits in metabolic syndrome- Janssen Pharma

Alzheimer's medication Reminyl XL/Razadyne (galantamine hydrobromide) from Janssen Pharma, appears to slash inflammation and insulin resistance in patients with metabolic...

Added 2 days ago Drug news

Alzheon, Inc makes presentation of data from three studies of ALZ 801, a proposed treatment for Alzheimers Disease at the AAIC meeting.

Alzheon, Inc.,announced data from the company’s three presentations at the Alzheimer’s Association International Conference (AAIC) held in London on July...

Added 2 days ago Drug news

EU Commission approves Reagila (cariprazine), for the treatment of schizophrenia .-Recordati + Gedeon Richter.

Recordati announces that Gedeon Richter Plc. was granted marketing authorization from the European Commission for Reagila (cariprazine), a novel antipsychotic...

Added 3 days ago Drug news

FDA maintains clinical hold on Proellex (telapristone acetate), a treatment for uterine fibroids.- Repros Therapeutics

Repros Therapeutics Inc has announced that it received preliminary feedback from the FDA on the Company's clinical development program for...

Added 3 days ago Drug news

FDA approves Nerlynx (neratinib) to treat patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy.- Puma Biotechnology

Puma Biotechnology announced that the FDA has approved Nerlynx (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor...

Added 3 days ago Drug news

Complete Response Letter from FDA for Evenity (romosozumab) as a treatment for postmenopausal women with osteoporosis. - Amgen +UCB.

Amgen and UCB announced that the FDA has issued a Complete Response Letter for the Biologics License Application (BLA) for...

Search all news articles